{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:48:50Z","timestamp":1777132130963,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.autrev.2026.104041","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:59:04Z","timestamp":1774583944000},"page":"104041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and clinical significance of anti\u2013NOR90 antibodies in systemic sclerosis: Results from a multicentre cohort and systematic literature review"],"prefix":"10.1016","volume":"25","author":[{"given":"Javier","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Morandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Roig-Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00ed","family":"Aguilar-Coll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"de Daniel-Bisbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arancha","family":"Alfranca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Valero-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther F.","family":"Vicente-Rabaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Miquell","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104041_bb0005","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104041_bb0010","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4049\/jimmunol.139.8.2579","article-title":"Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin","volume":"139","author":"Rodriguez-Sanchez","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104041_bb0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1084\/jem.174.5.1239","article-title":"Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor","volume":"174","author":"Chan","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2026.104041_bb0020","first-page":"1543","article-title":"Autoantibodies to NOR 90\/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response","volume":"29","author":"Dagher","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2026.104041_bb0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.31138\/mjr.29.3.120","article-title":"Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece","volume":"29","author":"Liaskos","year":"2018","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0035","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/rheumatology\/kes055","article-title":"Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population","volume":"51","author":"Low","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104041_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104041_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2024.03.035","article-title":"Clinical significance of the anti-nucleolar organizer region 90 antibodies (NOR90) in systemic sclerosis: analysis of the European scleroderma trials and research (EUSTAR) cohort and a systematic literature review","volume":"125","author":"Dima","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2026.104041_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejim.2024.09.011","article-title":"Clinical significance of the anti-nucleolar organizer region 90 antibodies (NOR90) in systemic sclerosis","volume":"131","author":"Lin","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2026.104041_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004580","article-title":"Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients","volume":"10","author":"Didier","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104041_bb0060","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/rheumatology\/keab575","article-title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","volume":"61","author":"Yamashita","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104041_bb0065","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/annrheumdis-2022-eular.1636","article-title":"Anti-NOR90 antibodies in the setting of connective tissue disease: clinical significance and comparison with a cohort of patients with systemic sclerosis [abstract POS0863]","volume":"81","author":"Biglia","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2026.104041_bb0070","article-title":"High prevalence of autoimmunity and cancer in anti-NOR90-positive patients: a multicenter observational study [abstract 2491]","volume":"77","author":"Due\u00f1as-Ochoa","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0075","first-page":"2002","article-title":"Anti-NOR90 antibody associated with paraneoplastic systemic sclerosis","volume":"40","author":"Duffau","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0080","first-page":"1720","article-title":"Comment on: anti-NOR90 antibody associated with paraneoplastic systemic sclerosis","volume":"41","author":"Valero","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0085","article-title":"Correlation between autoantibodies and internal organs involvement in Iranian systemic sclerosis patients","author":"Mottaghi","year":"2022","journal-title":"Immunopathol Persa"},{"key":"10.1016\/j.autrev.2026.104041_bb0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.5604\/17322693.1117543","article-title":"Serological profile of patients with systemic sclerosis","volume":"68","author":"Wielosz","year":"2014","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"10.1016\/j.autrev.2026.104041_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/pin.13221","article-title":"Antinuclear antibody pattern and autoantibody profiling of systemic sclerosis patients in a tertiary referral center in North India","volume":"72","author":"Machhua","year":"2022","journal-title":"Pathol Int"},{"key":"10.1016\/j.autrev.2026.104041_bb0100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2026.104041_bb0105","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2026.104041_bb0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104041_bb0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1756-185X.12322","article-title":"Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort","volume":"18","author":"Sujau","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104041_bb0120","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0125","first-page":"35","article-title":"A wide immunological profile in the diagnosis of progressive systemic sclerosis","volume":"24","author":"Krasimirova","year":"2016","journal-title":"Rheumatology (Bulgaria)"},{"key":"10.1016\/j.autrev.2026.104041_bb0130","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s10067-015-2981-3","article-title":"A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand","volume":"34","author":"Chang","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104041_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cca.2019.01.020","article-title":"Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population","volume":"491","author":"Liu","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2026.104041_bb0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/jcm12020657","article-title":"Autoantibodies and clinical correlations in polish systemic sclerosis patients: a cross-sectional study","volume":"12","author":"\u017bebryk","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2026.104041_bb0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08916934.2021.1907842","article-title":"Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests","volume":"54","author":"Alkema","year":"2021","journal-title":"Autoimmunity"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:20:00Z","timestamp":1777130400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1568997226000558"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104041","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical significance of anti\u2013NOR90 antibodies in systemic sclerosis: Results from a multicentre cohort and systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104041"}}